Purchase this article with an account.
J.M. Reed, J.J. Dajcs, J.T. Bush, K.S. Monds, R.J. O'Callaghan; Lysostaphin Therapy for Experimental Endophthalmitis Mediated by Various Species of Staphylococcus . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5559.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Lysostaphin is an enzyme that has been shown to efficiently kill Staphylococcus aureus in rabbit models of keratitis and endophthalmitis. This study was conducted to determine the effectiveness of lysostaphin for experimental endophthalmitis mediated by strains of six Staphylococcus species, including the most common agents of endophthalmitis.
The bacteria analyzed included 2 to 4 strains each of S. warneri, S. cohnii, S. simulus, S. capitis, S. haemolyticus, and S. epidermidis. Two S. epidermidis strains were methicillin resistant (MRSE). Strains were obtained from either the American Type Culture Collection or from Dr. David Stroman (Alcon Laboratories, Inc.). Log phase bacteria (50 colony forming units [CFU]) were injected into the vitreous of rabbit eyes (n ≥ 4 eyes per group). Lysostaphin (250 micrograms in 0.1 ml water) was injected at 8 hours postinfection (PI) and animals were sacrificed at 24 hours PI. To determine the log CFU per ml, vitreous was cultured in triplicate immediately upon collection and after serial dilution.
Eyes treated with lysostaphin had significantly fewer CFU per ml of vitreous than the untreated control for all species except S. haemolyticus and one MRSE strain.
A single treatment with lysostaphin caused a significant reduction in viable bacteria for nearly all strains tested; the exceptions were the S. haemolyticus strains and one MRSE strain.
This PDF is available to Subscribers Only